Pharmaceutical Executive

Pharmaceutical Executive Daily: FDA Advisory Committee Votes Unanimously in Favor of The Benefit-Risk Profile of Moderna's mRNA-1010

19 Jun 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, an FDA advisory committee votes unanimously in favor of the benefit-risk profile of Moderna's investigation...

Pharmaceutical Executive Daily: FDA Approves Utebzi and Capvaxive

18 Jun 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Biogen announces its second acquisition of 2026, a deal worth up to $1 billion for private immunology biote...

Pharmaceutical Executive Daily: Meaningfully Improving Therapy Persistence in Patient Support Programs

17 Jun 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, FDA staff release briefing documents flagging evidence gaps in Moderna's mRNA flu vaccine, a pharma roundup...

Pharmaceutical Executive Daily: FDA has Approved Skinvive by Juvéderm

16 Jun 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Elicio Therapeutics shares tumble after its Phase II Amplifgy-7P trial of KRAS-targeting immunotherapy ELI-...

Pharmaceutical Executive Daily: FDA Approves Two Indications of Keytruda in Combination with Welireg

15 Jun 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Boehringer Ingelheim's Brian Hilberdink argues that obesity innovation must evolve beyond the scale, a phar...

Pharmaceutical Executive Daily: Kardigan Sets Terms for $350 Million IPO

12 Jun 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Kardigan sets terms for a $350 million IPO that would value the cardiovascular biotech at approximately $1....

Pharmaceutical Executive Daily: China's Latest Policy Guidance

11 Jun 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Bruce Liu examines China's latest policy guidance establishing premium pricing and priority reimbursement a...

Pharmaceutical Executive Daily: Parabilis Medicines Prices Record-Breaking $670 Million IPO

10 Jun 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Parabilis Medicines prices a record-breaking $670 million IPO, Swedish biotech AlzeCure Pharma enters a col...

The Ron Lanton Report: From Innovation to Infrastructure

10 Jun 2026

Contributed by Lukas

In this episode, Ron Lanton draws on insights from the JP Morgan Healthcare Conference to explain how healthcare investment is shifting from backing n...

Pharmaceutical Executive Daily: GSK Acquires Nuvalent for $10.6 Billion

09 Jun 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, a pharma funding roundup covers two RNA-focused biotechs that secured fresh capital, GSK announces a $10.6 ...

Pharmaceutical Executive Daily: Roche and Nurix Therapeutics Announce Global Collaboration

08 Jun 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Roche and Nurix Therapeutics announce a global collaboration, a pharma M&A roundup covers three deals annou...

Pharmaceutical Executive Daily: Supreme Court Unanimously Rules in Favor of Hikma Pharmaceuticals in Skinny Label Case

05 Jun 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, the Supreme Court unanimously rules in favor of Hikma Pharmaceuticals in its patent dispute with Amarin ove...

Pharmaceutical Executive Daily: Alnylam Pharmaceuticals and Inceptive Nucleics Announce 3 Year Strategic Collaboration

04 Jun 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Eli Lilly escalates its 340B enforcement standoff by notifying covered entities of a five-business-day wind...

Navigating PBM Pitfalls: Protecting Revenue in a Complex Rebate Landscape

04 Jun 2026

Contributed by Lukas

In this episode of Pricing & Policy with Model N, Jesse Mendelsohn, senior vice president at Model N, joins host Mike Christel to offer a candid,...

Pharmaceutical Executive Daily: New FDA Draft Guidance Targets Gene Therapy Submission Burden

03 Jun 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Cam Olig of Prescryptive Health touches on the results of a new market access survey, Eli Lilly and Ascidia...

Pharmaceutical Executive Daily: FDA Sends Complete Response Letter for Cingulate's CTx-1301

02 Jun 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, FDA has accepted a new drug application for giredestrant under priority review, FDA also issues a complete ...

Pharmaceutical Executive Daily: FDA Approves Xocova

01 Jun 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, the FDA approves Shionogi's Xocova, a pharma M&A roundup covers Servier's acquisition of Edgewise Therapeut...

Pharmaceutical Executive Daily: WHO Identifies Priority Treatment Candidates for Ebola

29 May 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Harpreet Singh discusses the evolving regulatory landscape for biopharma, the World Health Organization i...

Pharmaceutical Executive Daily: CVS Health to Offer Zepbound and Foundayo

28 May 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, an FDA advisory committee weighs recommendations for the composition of the 2026–2027 Covid-19 vaccines...

Pharmaceutical Executive Daily: FDA Approves Hepcludex

26 May 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Eli Lilly announces three acquisitions totaling roughly $3 billion, the FDA approves Hepcludex as the fir...

Pharmaceutical Executive Daily: FDA Approves Datroway

22 May 2026

Contributed by Lukas

Pharmaceutical Executive Daily: What It Takes to Move Machine Learning

21 May 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Reuters reports that lower-priced oral GLP-1 pills from Eli Lilly and Novo Nordisk are drawing patients awa...

Pharmaceutical Executive Daily: Eli Lilly Acquires Engage Bio

20 May 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Eli Lilly announces a deal worth up to $202 million for Engage Biologics and its preclinical non-viral DNA...

Pharmaceutical Executive Daily: TrumpRx Expands to Offer Over 600 Generic Drugs

19 May 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the Trump administration expands TrumpRx to include more than 600 generic medicines, industry leaders ret...

Rethinking Pharma's Go-to-Market Formula

19 May 2026

Contributed by Lukas

In this episode of the Pharm Exec podcast, Mike Petroutsas, president and head of U.S. commercial at Astellas, shares the secrets to building a more ...

Pharmaceutical Executive Daily: FDA Approves Baxdrostat

18 May 2026

Contributed by Lukas

Pharmaceutical Executive Daily: FDA Approves AstraZeneca's Fasenra

15 May 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, FDA approves AstraZeneca's Fasenra as a new treatment for hypereosinophilic syndrome in patients 12 years a...

Pharmaceutical Executive Daily: FDA Approves Beqalzi and Inqovi

14 May 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, the FDA grants accelerated approval to BeOne Medicines' Beqalzi as the first and only BCL2 inhibitor for re...

Pharmaceutical Executive Daily: Rigel Pharmaceuticals Enters an Exclusive Global Licensing Agreement with Arvinas and Pfizer for Veppanu

13 May 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Rigel Pharmaceuticals enters an exclusive global licensing agreement with Arvinas and Pfizer for Veppanu, E...

Pharmaceutical Executive Daily: GSK Enters Collaboration to Support Launch of Bepirovirsen

11 May 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, GSK enters an exclusive collaboration with Sino Biopharmaceutical's CTTQ subsidiary to accelerate the launc...

Pharmaceutical Executive Daily: FDA Extends Review of Leqembi's sBLA

08 May 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA extends its priority review of a subcutaneous formulation of Leqembi, industry analysts examine h...

Pharmaceutical Executive Daily: Angelini Pharma Acquires Catalyst Pharmaceuticals in $4.1 Billion Agreement

07 May 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Angelini Pharma announces a $4.1 billion agreement to acquire Catalyst Pharmaceuticals, Incyte presents 24-...

Strengthening the Generic Drugs Supply Chain

06 May 2026

Contributed by Lukas

Natalie de Graaf, from the API Innovation Center, discusses a recent whitepaper detailing areas where the generic drugs pipeline is under stress.

Pharmaceutical Executive Daily: Zentalis Doses First Patient with Azenosertib in Phase III Trial

06 May 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Bayer agrees to acquire Perfuse Therapeutics for up to $2.45 billion and Madrigal obtains an exclusive glob...

Pharmaceutical Executive Daily: BioNTech Reports 2026 First Quarter Results

05 May 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Cellenkos announces FDA clearance of its investigational new drug application for CK0802, BioNTech releases...

Pharmaceutical Executive Daily: UCB to Acquire Candid Therapeutics

04 May 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, UCB announces a definitive agreement to acquire Candid Therapeutics for up to $2.2 billion, a new commentar...

Pharmaceutical Executive Daily: FDA Approves Auvelity

01 May 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, the FDA's Oncologic Drugs Advisory Committee votes a favorable benefit-risk profile for AstraZeneca's Truqa...

Pharmaceutical Executive Daily: Sanofi Appoints Belén Garijo as CEO

30 Apr 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Sanofi formally confirms its CEO leadership following a shareholder vote, US prescription drug spending i...

Pharmaceutical Executive Daily: Rocket Pharmaceuticals Sells Pediatric Disease Priority Review Voucher

29 Apr 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Rocket Pharmaceuticals announces a $180 million sale of its rare pediatric disease priority review voucher,...

Pharmaceutical Executive Daily: FDA Approves Breztri

28 Apr 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, we cover Sun Pharma's $11.75 billion acquisition of Organon and IMG Pharma's move to acquire Japanese OTC m...

Pharmaceutical Executive Daily: FDA Approves Caplyta for Adults with Schizophrenia

27 Apr 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Eli Lilly announces a definitive agreement to acquire Ajax Therapeutics for up to $2.3 billion, adding a fi...

Pharmaceutical Executive Daily: FDA Issues CRL to AbbVie

24 Apr 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA issues a complete response letter to AbbVie for a biologics license application, Regeneron moves ...

Pharmaceutical Executive Daily: FDA Expands Approvals for Tzield and Dupixent

23 Apr 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA expands the use of Tzield to young children to delay the onset of stage 3 type 1 diabetes, Dupixe...

The Ron Lanton Report: Where Innovations Happens

23 Apr 2026

Contributed by Lukas

In this episode, Ron Lanton examines how geography is becoming a central strategic variable in healthcare, as policy, trade dynamics, and infrastructu...

Pharmaceutical Executive Daily: Idvynso Receives FDA Approval

22 Apr 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA approves a new treatment for HIV-1 infection in adults, Amazon One Medical launches a GLP-1 weigh...

Pharmaceutical Executive Daily: UnitedHealth Raises Full-Year Profit Forecast

21 Apr 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, UnitedHealth raises its full-year profit forecast following stronger-than-expected first-quarter results,...

Pharmaceutical Executive Daily: Eli Lilly Acquires Kelonia Therapeutics

20 Apr 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Eli Lilly enters a $7 billion agreement to acquire Kelonia Therapeutics, the Trump administration issues ...

Inside Pharma's Revenue Engine: The Gross-to-Net Reckoning

17 Apr 2026

Contributed by Lukas

In the debut episode of Pricing & Policy with Model N — a new podcast series from Pharmaceutical Executive — Model N VP of product management...

Pharmaceutical Executive Daily: Eli Lilly Releases Updated Safety Data for Foundayo

16 Apr 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Eli Lilly releases updated safety data for its oral obesity pill Foundayo in response to an FDA post-approv...

Pharmaceutical Executive Daily: Obsidian and Galera Therapeutics Enter Merger Agreement

15 Apr 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, platform innovation continues to drive biotech investment across oncology and immunology, Obsidian Therap...

Pharmaceutical Executive Daily: AbbVie and Haisco Enter $745 Million Licensing Agreement

14 Apr 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, AbbVie licenses a portfolio of pain compounds from China's Haisco Pharmaceutical in a deal worth up to $745...

Pharmaceutical Executive Daily: FDA Issues Second CRL for Replimune's RP1 Melanoma Treatment

13 Apr 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, the FDA issues a second complete response letter for Replimune's RP1 in advanced melanoma, Regeneron and Te...

Pharmaceutical Executive Daily: China Approves Amgen's Tarlatamab for Previously Treated Extensive-Stage Small Cell Lung Cancer

10 Apr 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, China approves Amgen's tarlatamab for previously treated extensive-stage small cell lung cancer, a large st...

Why Branding is Pharma’s Most Undervalued Asset

10 Apr 2026

Contributed by Lukas

In this episode of Leading Edge With Ken Banta, The Vanguard Network founder and CEO is joined by branding strategist Andy Milligan, founding partner...

Pharmaceutical Executive Daily: Shionogi Receives a Contract Through BARDA's Project BioShield

09 Apr 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Shionogi receives a contract worth up to $482 million to bolster U.S. preparedness against drug-resistant b...

Pharmaceutical Executive Daily: Shah Capital's Plan to Vote Against Novavax Board Nominees

08 Apr 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, activist investor Shah Capital escalates its campaign against Novavax's board ahead of the company's annual...

Pharmaceutical Executive Daily: Wegovy HD Now Available in the U.S.

07 Apr 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Novo Nordisk launches Wegovy HD nationwide across the U.S., Gilead Sciences agrees to acquire German antibo...

Pharmaceutical Executive Daily: Neurocrine Biosciences Agrees to Acquire Soleno Therapeutics

06 Apr 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Neurocrine Biosciences agrees to acquire Soleno Therapeutics for $2.9 billion to gain Vykat XR, the first a...

Pharmaceutical Executive Daily: President Trump Imposes 100% Tariff for Branded Pharmaceuticals

03 Apr 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, President Trump signs an executive order imposing 100% tariffs on imported patented pharmaceuticals under S...

Pharmaceutical Executive Daily: Leadership Turnover Under Trump Administration

02 Apr 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, leadership turnover continues across key federal health agencies under the Trump administration, Shionogi...

Pharmaceutical Executive Daily: Trump Administration Delays Appeal of Federal Ruling Blocking Vaccine Policy Overhaul

01 Apr 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, the Trump administration delays its appeal of the federal ruling blocking RFK Jr.'s vaccine policy overhaul...

Pharmaceutical Executive Daily: Novo Nordisk's Wegovy Subscription Program

31 Mar 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Novo Nordisk launches the first multi-month subscription program for Wegovy targeting cash-paying patients ...

Pharmaceutical Executive Daily: Eli Lilly Presses U.K. Government to Raise NHS Drug Pricing

30 Mar 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Eli Lilly presses the U.K. government to overhaul its NHS drug pricing framework as a condition of resuming...

Pharmaceutical Executive Daily: Novartis Acquires Excellergy Inc.

27 Mar 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Novartis agrees to acquire Excellergy for up to $2 billion to advance a next-generation anti-IgE therapy wh...

Pharmaceutical Executive Daily: Trump Administration Misses Deadline to Nominate Permanent CDC Director

26 Mar 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, the Trump administration misses a statutory deadline to nominate a permanent CDC director, leaving the agen...

Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio

25 Mar 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, the FDA issues a warning letter to ImmunityBio over misleading promotional claims about its bladder cancer ...

Pharmaceutical Executive Daily: Bayer Shares Drop After Inclusive Capital Offloads Remaining Stake

24 Mar 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Bayer shares briefly dip after activist investor Inclusive Capital offloads its remaining stake at a loss, ...

Pharmaceutical Executive Daily: Pfizer Warns Shareholders to Reject Mini-Tender Offer

23 Mar 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Pfizer warns shareholders to reject an unsolicited mini-tender offer from Tutanota LLC seeking to purchase ...

Pharmaceutical Executive Daily: FDA Approves Wegovy HD

20 Mar 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Novartis agrees to acquire a pan-mutant-selective inhibitor from Synnovation Therapeutics in a deal worth u...

The Ron Lanton Report: When Policy Becomes a Capital Event

20 Mar 2026

Contributed by Lukas

The episode explores how regulatory signals across drug approvals, trade policy, AI governance, and drug pricing shape business strategy and investor ...

Pharmaceutical Executive Daily: Analysis on TrumpRx List Pricing

19 Mar 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, a new analysis finds that TrumpRx is listing prices for roughly a third of its featured drugs higher than w...

Pharmaceutical Executive Daily: Federal Judge Halts Vaccine Advisory Council Appointments

18 Mar 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, a federal judge blocks RFK Jr.'s reconstituted vaccine advisory committee and halts its policy changes, a n...

Pharmaceutical Executive Daily: Conflict in Middle East Disrupts Pharma Supply Chains

16 Mar 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, ongoing conflict in the Middle East is straining pharmaceutical supply routes to the Gulf region, Sentynl T...

Pharmaceutical Executive Daily: FDA Expands Approval for Arexvy

13 Mar 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, a new West Health-Gallup survey finds that more than 82 million Americans have cut back on daily expenses t...

Pharmaceutical Executive Daily: Senate Democrats Seeking Information on MFN Pharma Deals

12 Mar 2026

Contributed by Lukas

Moving CAR-T Beyond Oncology

11 Mar 2026

Contributed by Lukas

Vincent Hennemand discusses using these types of therapies to develop treatments for autoimmune conditions.

Pharmaceutical Executive Daily: FDA's New Guidance for Biosimilar Development

11 Mar 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, the FDA issues new draft guidance aimed at reducing the cost and complexity of biosimilar development, Novo...

Pharmaceutical Executive Daily: FDA Expands Approval of Leucovorin

10 Mar 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, the FDA approves leucovorin as the first-ever treatment for an ultra-rare genetic condition called cerebral...

Pharmaceutical Executive Daily: Vinay Prasad Set to Leave CBER for Second Time

09 Mar 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Vinay Prasad exits the FDA’s Center for Biologics Evaluation and Research for the second time in under ...

Pharmaceutical Executive Daily: Cognito Therapeutics and Nexcure Secure Financing Rounds

05 Mar 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Cognito Therapeutics and Nexcure secure new financing rounds to advance their pipelines, artificial intel...

Pharmaceutical Executive Daily: Pharma Industry's AI Adoption

04 Mar 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Antengene and UCB enter a billion-dollar global licensing agreement for a bispecific T-cell engager, Teva...

The Ongoing Impact of MFN Pricing

04 Mar 2026

Contributed by Lukas

Alice Valdur Curan discusses how the industry continues to strategize around this complicated order.

Pharmaceutical Executive Daily: Novo Nordisk Commits $506 Million to Ireland Manufacturing Site

03 Mar 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, industry leaders examine how to measure AI’s return on investment across the life sciences value chain,...

Pharmaceutical Executive Daily: FDA Approves Palynziq and Sogroya

02 Mar 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA approves an expanded indication for Palynziq in patients aged 12 and older, Sogroya becomes the f...

Pharmaceutical Executive Daily: FDA Approves Hernexeos

27 Feb 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA approves Hernexeos under a national priority voucher program, industry leaders explore the expans...

Pharmaceutical Executive Daily: Alkermes' CEO Succession Plan

26 Feb 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Alkermes outlines its CEO succession plan following Richard Pops’ retirement announcement, leadership c...

The Ron Lanton Report: Is Healthcare Consolidation Reaching Its Limits?

26 Feb 2026

Contributed by Lukas

The episode will explore structural implications for supply chains, distribution models, and international strategy, not a political discussion, but a...

Pharmaceutical Executive Daily: FDA Approves Braftovi

25 Feb 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA approves Braftovi for mutant metastatic colorectal cancer, Novo Nordisk and GSK announce major de...

Pharmaceutical Executive Daily: Novo Nordisk Announces Price Reductions for GLP-1 Products

24 Feb 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, AbbVie invests $380 million to expand API manufacturing capacity while Bora Pharmaceuticals and GSK enter...

Pharmaceutical Executive Daily: BioNTech Files Patent iInfringement Lawsuit Against Moderna

20 Feb 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, BioNTech files a patent infringement lawsuit against Moderna, the Supreme Court rules against a large num...

Pharmaceutical Executive Daily: FDA Plans to Remove Two Study Requirement for New Drug Approvals

19 Feb 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA reportedly removes its two-study requirement for new drug approvals, Hims & Hers enters a $1 bill...

Pharmaceutical Executive Daily: FDA Initiates Review of Moderna’s Seasonal Influenza Vaccine

18 Feb 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA begins reviewing Moderna’s seasonal flu vaccine under a revised regulatory approach, Eli Lilly ...

Pharmaceutical Executive Daily: FDA Approves New Dosing Schedule for Rybrevant Faspro

17 Feb 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA approves a monthly dosing schedule for Rybrevant Faspro, HHS Secretary Robert F. Kennedy Jr. revi...

Pharmaceutical Executive Daily: Disc Medicine Receives CRL from FDA for Bitopertin

16 Feb 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA issues a Complete Response Letter for Disc Medicine’s bitopertin in EPP, Edwards Lifesciences l...

Pharmaceutical Executive Daily: Eli Lilly's $1.5 Billion Stockpile of Orforglipron

13 Feb 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Eli Lilly builds a $1.5 billion stockpile of Orforglipron ahead of an FDA decision, PTC Therapeutics with...

Pharmaceutical Executive Daily: FDA Issues Refusal-to-File Letter to Moderna

11 Feb 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA issues a refusal-to-file letter to Moderna for its seasonal influenza vaccine as the company secu...

Pharmaceutical Executive Daily: Specialized Wealth Management for BioPharmaceutical Sales

10 Feb 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, frontline biopharma sales professionals are increasingly turning to specialized wealth management advisor...

Bets and Balances: Riding the Risk-and-Innovation Pendulum in Biotech

10 Feb 2026

Contributed by Lukas

In a podcast conversation with Pharm Exec, Ken Banta, founder and CEO of The Vanguard Network, and Andrew Hall, CEO of Consano Bio, discuss what effe...

Pharmaceutical Executive Daily: Hims & Hers Removes Access to New Compounded Semaglutide Pill

09 Feb 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Hims & Hers withdraws access to its compounded semaglutide pill following a controversy filled launch, ne...

Pharmaceutical Executive Daily: The Launch of TrumpRx

06 Feb 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, TrumpRx officially launches, the FDA moves against mass marketing of illegal copycat drugs, and AI emerge...